Skip to: Content
Skip to: Site Navigation
Skip to: Search

July 25, 2008 11:33:54 PM CDT


Stories related to: Novartis

Stories

4 Stories

  • April 2008
    • Final Trip for LSD Creator

      Final Trip for LSD Creator

      The Swiss scientist who formulated LSD and unwittingly helped lay the foundation of  '60s drug culture has died of a heart attack at the age of 102. Albert Hofmann, who called LSD his "problem child," discovered its hallucinatory properties while working on heart stimulants, reports the Washington Post . He believed laws eventually banning the drug halted important research into its potential use as a treatment for schizophrenia. More »

      Tags

      drugs   Novartis   hallucinogens   Aldous Huxley   LSD   Timothy Leary

    • Novartis, Nestle Agree to $39B Deal on Alcon

      Novartis, Nestle Agree to $39B Deal on Alcon

      Nestle and pharma giant Novartis continued swapping brands today, with Novartis, which sold Gerber to Nestle last year, agreeing to pay $39 billion for a 77% stake in eye-care company Alcon, reports the Wall Street Journal . The two-step deal—Novartis will pay $11 billion for 74 million shares this year and buy the remaining shares by 2011—is among the largest in Swiss history. More »

      Tags

      Novartis   Nestle

  • October 2007
    • Overdose Fears Prompt Recall of Infant Drugs

      Overdose Fears Prompt Recall of Infant Drugs

      Several drugmakers have recalled over-the-counter cough and cold products for infants over concerns about fatal overdoses, Reuters reports. Johnson & Johnson Wyeth and Novartis are among those recalling medicines; CVS said it will remove the products and generic equivalents. One professor took the criticism one step further: “There are really no good studies demonstrating that these medications work.” More »

      Tags

      drugs   FDA   recall   pharmaceutical   Wyeth   Johnson and Johnson   infants   Novartis   CVS

  • July 2007
    • Feds OK Alzheimer's Skin Patch

      Feds OK Alzheimer's Skin Patch

      A patch to treat symptoms of Alzheimer's disease cleared its final federal hurdle today, offering new hope to patients with the memory-sapping disorder—and the caretakers who worry about whether they're taking their meds. Exelon, which treats mild to moderate dementia, enters the bloodstream directly, regulating dosage and reducing the side effects associated with the medication in capsule form. More »

      Tags

      FDA   Alzheimer's   pharmaceutical companies   dementia   drug companies   Novartis

4 Stories

Today's Most Popular

Loading...

What is Newser?

2008 Codie Finalist

Newser gives you more news in less time. We search for the best and most important stories all over the web, read them for you, and deliver concise and sharp summaries—along with links to the full text. Newser provides a way to stay on top of an ever-expanding horizon of news and opinion—politics, sports, business, trends, technology, personalities, crimes, and controversies. Newser keeps you not just better informed, but, with our signature graphic interface and smart condensed format, more enjoyably informed.

Learn more »